<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952559</url>
  </required_header>
  <id_info>
    <org_study_id>16966</org_study_id>
    <secondary_id>I4V-MC-JAIP</secondary_id>
    <secondary_id>2018-000349-38</secondary_id>
    <nct_id>NCT03952559</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis</brief_title>
  <acronym>BREEZE-AD-PEDS</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug called baricitinib works and is safe in
      children and teenage participants with atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2019</start_date>
  <completion_date type="Anticipated">May 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 with a ≥2 Point Improvement</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants achieving IGA of 0 or 1 with a ≥2 point improvement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Open Label Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3009104</measure>
    <time_frame>Baseline through 2 Weeks</time_frame>
    <description>PK: Cmax of LY3009104</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Open Label PK: Area Under the Concentration Time Curve (AUC) of LY3009104</measure>
    <time_frame>Baseline through 2 Weeks</time_frame>
    <description>PK: AUC of LY3009104</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants achieving EASI75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving EASI90</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants achieving EASI90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on EASI Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on EASI Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SCORing Atopic Dermatitis 75 (SCORAD75)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants achieving SCORAD75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a 4-Point Improvement in Itch Numeric Rating Scale (NRS) for Participants ≥10 Years Old</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants achieving a 4-point improvement in Itch NRS for participants ≥10 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving EASI50</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants achieving EASI50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving IGA of 0</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants achieving IGA of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in SCORAD</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in SCORAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SCORAD90</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants achieving SCORAD90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Surface Area (BSA) Affected</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in BSA affected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Skin Infections Requiring Antibiotic Treatment</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Percentage of participants developing skin infections requiring antibiotic treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days without Use of Background Topical Corticosteroid (TCS)</measure>
    <time_frame>Baseline through 16 Weeks</time_frame>
    <description>Mean number of days without use of background TCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Gram Quantity of TCS Use (Tube Weights)</measure>
    <time_frame>Baseline through 16 Weeks</time_frame>
    <description>Mean gram quantity of TCS use (tube weights)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Itch NRS</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in itch NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Parent-Reported Itch Severity Measure (PRISM) for Participants &lt;10 years old</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the PRISM for participants &lt;10 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Patient-Oriented Eczema Measure (POEM) Total Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the POEM total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Global Impression of Severity-Atopic Dermatitis (PGI-S-AD) Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in PGI-S-AD score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS)-Pediatric Depression</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the PROMIS-pediatric depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the PROMIS-Pediatric Anxiety</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the PROMIS-pediatric anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Children's/Infants's Dermatology Life Quality Index (CDLQI/IDQOL)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the CDLQI/IDQOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Work Productivity and Activity Impairment: Atopic Dermatitis - Caregiver (WPAI-AD-CG) Score</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the WPAI-AD-CG score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the European Quality of Life-5 Dimensions-Youth (EQ-5D-Y)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline on the EQ-5D-Y</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Score of Item 2 of the Atopic Dermatitis Sleep Scale (ADSS) for Participants ≥10 Years Old</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in the score of item 2 of the ADSS for participants ≥10 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Skin Pain NRS for Participants ≥10 Years Old</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
    <description>Change from baseline in Skin Pain NRS for participants ≥10 years old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability Assessment (PK Lead-In)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Participants were evaluated for baricitinib acceptability using a 5-category questionnaire. Participants were asked to answer one of the following to describe the ease of use of baricitinib: Very difficult (or hard), difficult (or hard), neither easy nor hard, easy, or very easy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability Assessment (PK Lead-In)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Participants were evaluated for baricitinib palatability using a 5-category questionnaire. Participants were asked to answer one of the following to describe the taste and smell of baricitinib: Disliked very much, disliked, neither liked nor disliked, liked, or like very much.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Immunoglobulin G (IgG) Titers</measure>
    <time_frame>Pre-Vaccination to 12 Weeks Post-Vaccination</time_frame>
    <description>Change of IgG titers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height Growth Rate (in Centimeters/Year)</measure>
    <time_frame>124 Weeks</time_frame>
    <description>Height growth rate (in centimeters/year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3009104</measure>
    <time_frame>Baseline through 16 Weeks</time_frame>
    <description>PK: Cmax of LY3009104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of LY3009104</measure>
    <time_frame>Baseline through 16 Weeks</time_frame>
    <description>PK: AUC of LY3009104</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">465</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Baricitinib Open Label High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally. Placebo administered orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally. Placebo administered orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally. Placebo administered orally to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally. Matching placebo administered orally to maintain the blind.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <arm_group_label>Baricitinib Mid Dose</arm_group_label>
    <arm_group_label>Baricitinib Open Label High Dose</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical corticosteroid</intervention_name>
    <description>Administered as standard-of-care</description>
    <arm_group_label>Baricitinib High Dose</arm_group_label>
    <arm_group_label>Baricitinib Low Dose</arm_group_label>
    <arm_group_label>Baricitinib Mid Dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At or above the 5th percentile of weight for age.

          -  Have been diagnosed with moderate to severe atopic dermatitis for at least 12 months
             (if 6 years old or older) or at least 6 months (if 2 up to 6 years old).

          -  Have had inadequate response or intolerance to existing topical (applied to the skin)
             medications within 6 months preceding screening.

          -  Are willing to discontinue certain treatments for eczema (such as systemic and topical
             treatments during a washout period).

          -  Agree to use emollients daily.

        Exclusion Criteria:

          -  Are currently experiencing or have a history of other concomitant skin conditions
             (e.g., psoriasis or lupus erythematosus), or a history of erythrodermic, refractory,
             or unstable skin disease that requires frequent hospitalizations and/or intravenous
             treatment for skin infections.

          -  A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode
             of eczema herpeticum in the past.

          -  Participants who are currently experiencing a skin infection that requires treatment,
             or is currently being treated, with topical or systemic antibiotics.

          -  Have any serious illness that is anticipated to require the use of systemic
             corticosteroids or otherwise interfere with study participation or require active
             frequent monitoring (e.g., unstable chronic asthma).

          -  Have been treated with the following therapies:

               -  Monoclonal antibody for less than 5 half-lives prior to beginning study
                  treatment.

               -  Received prior treatment with any oral Janus kinase (JAK) inhibitor.

               -  Received any parenteral corticosteroids administered by intramuscular or
                  intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks
                  prior to planned initiation of study drug or are anticipated to require
                  parenteral injection of corticosteroids during the study.

          -  Have had an intra-articular corticosteroid injection within 2 weeks prior to study
             entry or within 6 weeks prior to planned initiation of study drug.

          -  Have high blood pressure characterized by a repeated systolic or diastolic blood
             pressure &gt;95th percentile based on age, sex and height.

          -  Have had major surgery within the past eight weeks or are planning major surgery
             during the study.

          -  Have experienced any of the following within 12 weeks of screening: venous
             thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart
             disease, stroke, or New York Heart Association Stage III/IV heart failure.

          -  Have a history of VTE or are considered at high risk of VTE as deemed by the
             investigator.

          -  Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver
             disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative
             disease or neuropsychiatric disorders or any other serious and/or unstable illness.

          -  Have a current or recent clinically serious viral, bacterial, fungal, or parasitic
             infection including herpes zoster (shingles or chicken pox), tuberculosis.

          -  Have specific laboratory abnormalities.

          -  Have received certain treatments that are contraindicated.

          -  Pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro de Investigaciones Metabólicas (CINME)</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1056ABJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Dra. De Salvo</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Fundacion CIDEA</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Neumonología y Dermatología</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1425BEA</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The Sydney Children's Hospitals Network</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61298450179</phone>
    </contact>
    <investigator>
      <last_name>Li-Chuen Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research Pty Ltd</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61730391311</phone>
    </contact>
    <investigator>
      <last_name>Lynda Jane Spelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Childrens Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61393455570</phone>
    </contact>
    <investigator>
      <last_name>John Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4331638513055</phone>
    </contact>
    <investigator>
      <last_name>Barbara Binder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <state>Vienna</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4314040032430</phone>
    </contact>
    <investigator>
      <last_name>Zsolt Szepfalusi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sozialmed. Zentrum Ost - Donauspital</name>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>431288024102</phone>
    </contact>
    <investigator>
      <last_name>Gregor Holzer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IDERJ - Instituto de Dermatologia e Estética do Brasil</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22470-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Fundação Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Instituto Brasil de Pesquisa Clínica - IBPCLIN</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20241180</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>552125277979</phone>
    </contact>
    <investigator>
      <last_name>Nidia Francisco Chicralla da Rocha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Servidor Publico Estadual</name>
      <address>
        <city>São Paulo</city>
        <zip>04039-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice v Motole</name>
      <address>
        <city>Praha 5</city>
        <state>Hl. M. Praha</state>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+420224435743</phone>
    </contact>
    <investigator>
      <last_name>Alena Machovcova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Na Bulovce</name>
      <address>
        <city>Praha 8</city>
        <state>Hl. M. Praha</state>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>420266082359</phone>
    </contact>
    <investigator>
      <last_name>Jana Hercogova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kozni oddeleni</name>
      <address>
        <city>Novy Jicin</city>
        <state>Moravskoslezsky Kraj</state>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>420556773533</phone>
    </contact>
    <investigator>
      <last_name>Marie Selerova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>420495836373</phone>
    </contact>
    <investigator>
      <last_name>Jirina Bartonova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorium Profesora Arenbergera</name>
      <address>
        <city>Praha 1</city>
        <zip>110 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>420224232468</phone>
    </contact>
    <investigator>
      <last_name>Petr Arenberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <state>Cedex</state>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33134232880</phone>
    </contact>
    <investigator>
      <last_name>Emmanuel Mahe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33298223315</phone>
    </contact>
    <investigator>
      <last_name>Claire Abasq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru De Nantes Hotel-Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33240084086</phone>
    </contact>
    <investigator>
      <last_name>Sébastien Barbarot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Hopital de L'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33492036119</phone>
    </contact>
    <investigator>
      <last_name>Jean Philippe Lacour</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33567771876</phone>
    </contact>
    <investigator>
      <last_name>Juliette Mazereeuw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4969630183115</phone>
    </contact>
    <investigator>
      <last_name>Andreas Pinter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>492518356558</phone>
    </contact>
    <investigator>
      <last_name>Nina Magnolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>493514580</phone>
    </contact>
    <investigator>
      <last_name>Susanne Abraham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Katholisches Kinderkrankenhaus Wilhelmstift</name>
      <address>
        <city>Hamburg</city>
        <zip>22149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>494067377202</phone>
    </contact>
    <investigator>
      <last_name>Peter H. Höger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oroshaza Varosi Onkormanyzat Korhaza</name>
      <address>
        <city>Oroshaza</city>
        <state>Bekes</state>
        <zip>5900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3668411166</phone>
    </contact>
    <investigator>
      <last_name>Piroska Szabo-Dosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SZTE AOK Borgyogyaszati es Allergologiai Klinika</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>3662511151</phone>
    </contact>
    <investigator>
      <last_name>Lajos Kemeny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allergo-Derm Bakos Kft</name>
      <address>
        <city>Szolnok</city>
        <state>Jasz-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>36209819476</phone>
    </contact>
    <investigator>
      <last_name>Noemi Bakos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All India Institue of Medical Sciences (AIIMS)</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>911126864851</phone>
    </contact>
    <investigator>
      <last_name>Vinod Kumar Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Byramjee Jeejeebhoy Medical College &amp; Civil Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380016</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>GMERS Medical College &amp; Hospital</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390021</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Dr. D. Y. Patil Medical College &amp; Hospital</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>400706</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>8850635503</phone>
    </contact>
    <investigator>
      <last_name>Sharmila Patil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seth GS Medical College &amp; KEM Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharshtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>9969668905</phone>
    </contact>
    <investigator>
      <last_name>Vidya Kharkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifepoint Multispecialty Hsptl</name>
      <address>
        <city>Wakad</city>
        <state>Pune</state>
        <zip>411057</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education &amp; Research</name>
      <address>
        <city>Chandigarh</city>
        <state>Punjab</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>9815924777</phone>
    </contact>
    <investigator>
      <last_name>Sanjeev Handa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College &amp; LNJP, GB Pant Hospitals</name>
      <address>
        <city>New Delhi</city>
        <zip>110 002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>09818244340</phone>
    </contact>
    <investigator>
      <last_name>Rashmi Sarkar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aakash Healthcare Super Speciality Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110075</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>9810042030</phone>
    </contact>
    <investigator>
      <last_name>Pooja Chopra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ha'Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>97246494006</phone>
    </contact>
    <investigator>
      <last_name>Michael Ziv</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>97286400653</phone>
    </contact>
    <investigator>
      <last_name>Amir Horev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>97235302419</phone>
    </contact>
    <investigator>
      <last_name>Shoshana Greenberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972527360093</phone>
    </contact>
    <investigator>
      <last_name>Yaacov Mashiah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Masaki Futamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukuyama City Hospital</name>
      <address>
        <city>Fukuyama-shi</city>
        <state>Hiroshima</state>
        <zip>721-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Masanori Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Takeda Derm Skin Care Clin</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>004-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Osamu Takeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Sagamihara Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>252-0392</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Motohiro Ebisawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Japan National Hospital Organization Mie Hospital</name>
      <address>
        <city>Tsu-shi</city>
        <state>Mie</state>
        <zip>514-0125</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Takao Fujisawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kume Clinic</name>
      <address>
        <city>Nishi-ku Sakai-shi</city>
        <state>Osaka</state>
        <zip>593-8324</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Akihiro Kume</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senri-Chuo Hanafusa Dermatology Clinic</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <zip>560-0085</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Takaaki Hanafusa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital</name>
      <address>
        <city>Shimotsuga-Gun</city>
        <state>Tochigi</state>
        <zip>321 0293</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Shigemi Yoshihara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tokyo Rosai Hospital</name>
      <address>
        <city>Ota-Ku</city>
        <state>Tokyo</state>
        <zip>143-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Ken Hayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shinjuku Minamiguchi Dermatology</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Toshitathu Nogita</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Matsuda Tomoko Dematological Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>819 0167</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Tomoko Matsuda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consultorio Privado de la Dra. Villanueva</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44657</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>523336735023</phone>
    </contact>
    <investigator>
      <last_name>Delfina Guadalupe Villanueva Quintero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>NL</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>528183486173</phone>
    </contact>
    <investigator>
      <last_name>Gloria Maria Rosales Solis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Aplicadas a la Neurociencia A.C</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CRI Centro Regiomontano de Investigación</name>
      <address>
        <city>Monterrey</city>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Arke Estudios Clinicos S.A. de C.V.</name>
      <address>
        <city>Veracruz</city>
        <zip>91910</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Dermed Centrum Medyczne Sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48426631444</phone>
    </contact>
    <investigator>
      <last_name>Aleksandra Kaszuba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Rewerska DIAMOND CLINIC</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>31-209</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48694959892</phone>
    </contact>
    <investigator>
      <last_name>Barbara Rewerska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych, PI House</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>48587192222</phone>
    </contact>
    <investigator>
      <last_name>Aleksandra Anna Okuniewska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GBUZ Clinical dermatology and venereological dispensary</name>
      <address>
        <city>Krasnodar</city>
        <state>Krasnodarskiy Kray</state>
        <zip>350020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>78612552166</phone>
    </contact>
    <investigator>
      <last_name>Alkes Aslancherievich Khotko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Healthcare Instit Tula Reg Dermatov Dispensary</name>
      <address>
        <city>Tula</city>
        <state>Tul'skaja Oblast</state>
        <zip>300053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>79109447535</phone>
    </contact>
    <investigator>
      <last_name>Valentina Sorotskaya</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Center of Children`s Health</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>74991340889</phone>
    </contact>
    <investigator>
      <last_name>Nikolay N Murashkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>74995585828</phone>
    </contact>
    <investigator>
      <last_name>Olga Zhukova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>932532100</phone>
    </contact>
    <investigator>
      <last_name>Asuncion Vicente Villa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34911916481</phone>
    </contact>
    <investigator>
      <last_name>Gaston Roustan Gullon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria De Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34948255400</phone>
    </contact>
    <investigator>
      <last_name>Agustin Espana Alonso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>935537007</phone>
    </contact>
    <investigator>
      <last_name>Esther Roe Crespo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34915035900</phone>
    </contact>
    <investigator>
      <last_name>Antonio Torrelo Fernandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra-Sede Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28022</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34948255400</phone>
    </contact>
    <investigator>
      <last_name>Agustin Espana Alonso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34917277231</phone>
    </contact>
    <investigator>
      <last_name>Raul Lucas Laguna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Especialidades Mollabao</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34986800269</phone>
    </contact>
    <investigator>
      <last_name>Angeles Florez Menendez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital beider Basel UKBB</name>
      <address>
        <city>Basel</city>
        <state>Basel Stadt</state>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>41612654359</phone>
    </contact>
    <investigator>
      <last_name>Karin Hartmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>41442668281</phone>
    </contact>
    <investigator>
      <last_name>Lisa Weibel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>833401</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>886975056539</phone>
    </contact>
    <investigator>
      <last_name>Ji-Chen Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University- Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>886222490088 ext.2388</phone>
    </contact>
    <investigator>
      <last_name>Woan-Ruoh Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40201</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>886424739595 ext. 34511</phone>
    </contact>
    <investigator>
      <last_name>Po-Ju Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>886223123456</phone>
    </contact>
    <investigator>
      <last_name>Chia-Yu Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Taipei</name>
      <address>
        <city>Taipei</city>
        <zip>10508</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>886227135211</phone>
    </contact>
    <investigator>
      <last_name>I-Hsin Shih</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>886975366337</phone>
    </contact>
    <investigator>
      <last_name>Chin-Yi Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas's Hospital</name>
      <address>
        <city>Waterloo</city>
        <state>London</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+442071887188</phone>
    </contact>
    <investigator>
      <last_name>Carsten Flohr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's MedicaL Centre/University of Nottingham</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>441159249924</phone>
    </contact>
    <investigator>
      <last_name>Tang Kyle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G514TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>441412016910</phone>
    </contact>
    <investigator>
      <last_name>Paula Elizabeth Beattie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/atopic-dermatitis--eczema-/JAIP#?postal=</url>
    <description>A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis (BREEZE-AD-PEDS)</description>
  </link>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eczema</keyword>
  <keyword>atopic eczema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

